"[874FEAD01560]" . "InTech: Open Access Publisher" . "P(NT13836)" . "Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs" . . "RIV/00023736:_____/13:00010723!RIV14-MZ0-00023736" . . . . . "1"^^ . "37"^^ . . . "Fuchs, Ota" . "Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs"@en . "1"^^ . . . "Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs" . . "10.5772/52099" . . . "Rijeka" . "Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs"@en . "978-953-51-1127-6" . "http://dx.doi.org/10.5772/52099" . "Leukemia" . . "244"^^ . . . "elderly patients; MDS; AML; epigenetic cancer drug; treatment"@en . . "Acute myeloid leukemia (AML) is associated with poor prognosis in elderly patients. More effective, less toxic therapies for older patients with AML who are not eligible for standard intensive induction therapy or have refractory or relapsed disease after chemotherapy are urgently needed. Epigenetic approaches with hypomethylating agents and histone deacety lase inhibitors and immunomodulatory drugs used in advance in the treatment of patients with myelodysplastic syndrome (MDS) have been also studied in patients with AML [1-15]." . "RIV/00023736:_____/13:00010723" . "111741" . "Acute myeloid leukemia (AML) is associated with poor prognosis in elderly patients. More effective, less toxic therapies for older patients with AML who are not eligible for standard intensive induction therapy or have refractory or relapsed disease after chemotherapy are urgently needed. Epigenetic approaches with hypomethylating agents and histone deacety lase inhibitors and immunomodulatory drugs used in advance in the treatment of patients with myelodysplastic syndrome (MDS) have been also studied in patients with AML [1-15]."@en . . .